Ryan Christopher Clark

This inventor holds 18 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 7 EPO patents. Top assignees: Novira Therapeutics, Inc., Amira Pharmaceuticals, Inc., Merck Patent Gmbh. Active years: 2014-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ryan Christopher Clark. Retrieved from https://idiyas.com/inventor/ryan-christopher-clark

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 7)

% Patents Active = 66.7

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 4)

Average Co-Inventor Count = 5.8

ph-index = 5

Forward Citations = 86(Granted Patents)

Company Filing History:

6 out of 44

Novira Therapeutics, Inc.

patents

5 out of 23

Amira Pharmaceuticals, Inc.

Tempest Therapeutics, Inc.

patents

Years Active: 2014-2023

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11666557 - Triazolone compounds and uses thereof (2023-06-06),

2. 10710959 - Sulfide alkyl compounds for HBV treatment (2020-07-14),

3. 10568871 - Triazolone compounds and uses thereof (2020-02-25),

4. 10428041 - Pyridyl reverse sulfonamides for HBV treatment (2019-10-01),

5. 10392375 - Heteroaryl compounds as IRAK inhibitors and uses thereof (2019-08-27),

6. 10196351 - Sulfide alkyl compounds for HBV treatment (2019-02-05),

7. 10160742 - Pyridyl reverse sulfonamides for HBV treatment (2018-12-25),

8. 10059701 - Heteroaryl compounds as IRAK inhibitors and uses thereof (2018-08-28),

9. 10000456 - Polycyclic compounds as lysophosphatidic acid receptor antagonists (2018-06-19),

10. 9969710 - Heteroaryl compounds as IRAK inhibitors and uses thereof (2018-05-15),

11. 9765050 - Pyridyl reverse sulfonamides for HBV treatment (2017-09-19),

12. 9676754 - Triazolone compounds and uses thereof (2017-06-13),

13. 9624182 - Compounds as lysophosphatidic acid receptor antagonists (2017-04-18),

14. 9597332 - Sulfide alkyl compounds for HBV treatment (2017-03-21),

15. 9505728 - Triazolone compounds and uses thereof (2016-11-29),

Title: Innovator Ryan Christopher Clark: Pioneering Advances in Cancer Treatment

Introduction: Ryan Christopher Clark is a prominent inventor based in San Diego, CA, known for his significant contributions to medical innovations. With an impressive portfolio of 18 patents, Ryan focuses primarily on compounds and methods for treating various forms of cancer and viral infections. His groundbreaking work has the potential to change the landscape of therapeutic treatments.

Latest Patents: Among his latest patents is the invention related to triazolone compounds and their uses. This innovation encompasses compounds of Formula I and their pharmaceutically acceptable salts, which are crucial in treating cancers such as prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma, and others. The invention outlines methods for effective treatment through pharmaceutical compositions and includes the administration of selective PPARα antagonists. Additionally, Ryan's patent concerning sulfide alkyl compounds focuses on methods to inhibit HBV infections, providing an essential therapeutic avenue for affected individuals.

Career Highlights: Over his career, Ryan has made significant strides in the pharmaceutical industry working with esteemed companies such as Novira Therapeutics, Inc. and Amira Pharmaceuticals, Inc. His innovative research and development in drug formulation and delivery systems highlight his commitment to improving patient outcomes through advanced medicinal solutions.

Collaborations: Throughout his career, Ryan has worked alongside talented individuals such as Nicholas Simon Stock and Jason Duarte Jacintho. These collaborations have been instrumental in enhancing research capabilities and fostering innovative approaches to drug development.

Conclusion: Ryan Christopher Clark exemplifies the spirit of innovation in the medical field through his dedication to finding new treatments for cancer and viral infections. With practical applications stemming from his numerous patents, Ryan continues to contribute to the advancement of therapeutic methodologies that could impact countless lives. As he forges ahead, his work remains a testament to the power of scientific creativity and collaboration in driving meaningful change.

Profile summary based on public USPTO records.